J
Jian Jin
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 279
Citations - 13690
Jian Jin is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Methyltransferase & Epigenetics. The author has an hindex of 52, co-authored 267 publications receiving 10178 citations. Previous affiliations of Jian Jin include Ohio State University & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan,Martin C. Whittle,Kazuhiro Nakamura,Amy N. Abell,Alicia A. Midland,Jon S. Zawistowski,Nancy Lassignal Johnson,Deborah A. Granger,Nicole Vincent Jordan,David B. Darr,Jerry Usary,Pei Fen Kuan,David M. Smalley,Ben Major,Xiaping He,Katherine A. Hoadley,Bing Zhou,Norman E. Sharpless,Charles M. Perou,William Y. Kim,Shawn M. Gomez,Xin Chen,Jian Jin,Stephen V. Frye,H. Shelton Earp,Lee M. Graves,Gary L. Johnson +26 more
TL;DR: The inhibitor-induced RTK profile suggested a kinase inhibitor combination therapy that produced GEMM tumor apoptosis and regression where single agents were ineffective, allowing rational design of combination therapies for cancer.
Journal ArticleDOI
The promise and peril of chemical probes.
Cheryl H. Arrowsmith,James E. Audia,Christopher M. Austin,Jonathan B. Baell,Jonathan Bennett,Julian Blagg,C. Bountra,Paul Brennan,Peter Brown,Mark E. Bunnage,Carolyn Buser-Doepner,Robert M. Campbell,Adrian Carter,Philip Cohen,Robert A. Copeland,Ben Cravatt,Jayme L. Dahlin,Dashyant Dhanak,Aled M. Edwards,Mathias Frederiksen,Stephen V. Frye,Nathanael S. Gray,Charles E. Grimshaw,David Hepworth,Trevor Howe,Kilian Huber,Jian Jin,Stefan Knapp,Joanne Kotz,Ryan G. Kruger,Derek B. Lowe,Mary M. Mader,Brian D. Marsden,Anke Mueller-Fahrnow,Susanne Müller,Ronan C. O'Hagan,John P. Overington,Dafydd R. Owen,Saul H Rosenberg,Bryan L. Roth,Ruth A. Ross,Matthieu Schapira,Stuart L. Schreiber,Brian K. Shoichet,Michael Sundström,Giulio Superti-Furga,Jack Taunton,Leticia Toledo-Sherman,Chris Walpole,Michael A. Walters,Timothy M. Willson,Paul Workman,Robert N. Young,William J. Zuercher +53 more
TL;DR: A community-driven wiki resource to improve quality and convey current best practice on chemical probes, and to help address shortcomings of poor quality or that are used incorrectly generate misleading results.
Journal ArticleDOI
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi,Dalia Barsyte-Lovejoy,Feng Liu,Sylvie Rival-Gervier,Abdellah Allali-Hassani,Viviane Labrie,Tim J. Wigle,Peter A. DiMaggio,Gregory A. Wasney,Alena Siarheyeva,Aiping Dong,Wolfram Tempel,Sun Chong Wang,Sun Chong Wang,Xin Chen,Irene Chau,Thomas J. Mangano,Xi Ping Huang,Catherine Simpson,Samantha G. Pattenden,Jacqueline L. Norris,Dmitri Kireev,Ashutosh Tripathy,Aled M. Edwards,Bryan L. Roth,William P. Janzen,Benjamin A. Garcia,Arturas Petronis,James Ellis,Peter Brown,Stephen V. Frye,Cheryl H. Arrowsmith,Jian Jin +32 more
TL;DR: UNC0638 is reported, an inhibitor of G9a and GLP with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets, and markedly reduced the clonogenicity of MCF7 cells and disproportionately affected several genomic loci encoding microRNAs.
Journal ArticleDOI
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Kyle D. Konze,Anqi Ma,Fengling Li,Dalia Barsyte-Lovejoy,Trevor Parton,Christopher J. MacNevin,Feng Liu,Cen Gao,Xi Ping Huang,Ekaterina Kuznetsova,Marie Rougie,Alice Jiang,Samantha G. Pattenden,Jacqueline L. Norris,Lindsey I. James,Bryan L. Roth,Peter Brown,Stephen V. Frye,Cheryl H. Arrowsmith,Klaus M. Hahn,Gang Greg Wang,Masoud Vedadi,Jian Jin +22 more
TL;DR: UNC1999 was the first orally bioavailable inhibitor that has high in vitro potency for wild-type and mutant EZH2 as well as EzH1, a closely related H3K27 methyltransferase that shares 96% sequence identity with EZh2 in their respective catalytic domains.
Journal ArticleDOI
Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Hsien-Sung Huang,John A. Allen,Angela M. Mabb,Ian F. G. King,Jayalakshmi Miriyala,Bonnie Taylor-Blake,Noah Sciaky,J. Walter Dutton,Hyeong Min Lee,Xin Chen,Jian Jin,Arlene S. Bridges,Mark J. Zylka,Bryan L. Roth,Benjamin D. Philpot +14 more
TL;DR: Paternal expression of Ube3a remained elevated in a subset of spinal cord neurons for at least 12 weeks after cessation of topotecan treatment, indicating that transient topoisomerase inhibition can have enduring effects on gene expression.